Pineal gland hypermetabolic involvement without central nervous system symptoms in a pediatric patient with primary nodular sclerosis subtype classical Hodgkin Lymphoma

2021 ◽  
pp. 1-6
Author(s):  
Ryan E. Kokoska ◽  
Eric E. Beltz ◽  
Jodi L. Smith ◽  
Bassem I. Razzouk
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Pineal Gland ◽  
Hodgkin Lymphoma ◽  
Pediatric Patient ◽  
Classical Hodgkin Lymphoma ◽  
Nodular Sclerosis

scholarly journals Classical Hodgkin Lymphoma involving the central nervous system (brain) – an unusual presentation

2014 ◽  
Vol 2 (3) ◽  
pp. 88-92 ◽  
Author(s):  
Sarah Alexandra Blydenstein ◽  
Moosa Patel ◽  
Vinitha Philip ◽  
Atul Lakha ◽  
Sugeshnee Pather ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Hodgkin Lymphoma ◽  
Unusual Presentation ◽  
Classical Hodgkin Lymphoma ◽  
The Central Nervous System

scholarly journals OT-04 * PRIMARY CENTRAL NERVOUS SYSTEM NON HODGKIN LYMPHOMA IN A PEDIATRIC PATIENT WITHOUT IMMUNODEFICIENCY RELATED. CASE REPORT AND LITERATURE REVIEW

2015 ◽  
Vol 17 (suppl 3) ◽  
pp. iii29-iii29
Author(s):  
M. R. Aguilar-Ortiz ◽  
R. Cardenas-Cardos ◽  
L. Velasco-Hidalgo ◽  
P.-M. Pasquel-Garcia-Vazquez ◽  
R. Rivera-Luna ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Case Report ◽  
Literature Review ◽  
Hodgkin Lymphoma ◽  
Pediatric Patient ◽  
Related Case ◽  
Non Hodgkin Lymphoma

Classical Nodular Sclerosis Hodgkin Lymphoma Presenting with Central Nervous System Disease

2007 ◽  
Vol 100 (5) ◽  
pp. 549-550 ◽  
Author(s):  
Akshay K. Gupta ◽  
Dennis Meisner ◽  
Neetu Talreja ◽  
Ryan Smith ◽  
Steven H. Swerdlow
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Hodgkin Lymphoma ◽  
Central Nervous System Disease ◽  
Nervous System Disease ◽  
Nodular Sclerosis ◽  
System Disease

scholarly journals RARE-29. PRIMARY CENTRAL NERVOUS SYSTEM NON-HODGKIN LYMPHOMA IN AN 11-YEAR-OLD BOY: A CASE REPORT

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii448-iii448
Author(s):  
Jorge Luis Ramírez-Melo ◽  
Regina M Navarro-Martin del Campo ◽  
Manuel D Martinez-Albarran ◽  
Fernando Sánchez-Zubieta ◽  
Ana L Orozco-Alvarado ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Hodgkin Lymphoma ◽  
Central Nervous System Lymphoma ◽  
Complete Response ◽  
High Dose ◽  
Illustrative Case ◽  
Tumor Biopsy ◽  
Non Hodgkin Lymphoma ◽  
The Right

Abstract BACKGROUND Primary central nervous system lymphoma (PCNSL) are very rare in children. CLINICAL CASE: An 11-year-old male presented with a 2 months history with myoclonic movements in the upper right limb, and a sudden frontal headache, gait disturbance due to right hemiparesis and an ipsilateral convulsive episode. Upon admission he had critical condition, with hypertensive skull syndrome, Glasgow of 12, Karnofsky 40%, right hemiparesis, swallowing disorder, facial paralysis, and loss of photo motor reflex and unilateral amaurosis. A CT and MRI showed a huge tumor mass in the left tempo-parietal region, infiltrating the white matter and shifting the midline. A Tumor biopsy was done, and reported diffuse small cell non-Hodgkin lymphoma of high-grade, Burkitt type. Systemic lymphoma workup was negative. He received six cycles of chemotherapy based on high dose methotrexate, rituximab and triple intrathecal.After the second cycle an ophthalmologic evaluation was done, and found infiltration to the right retina, for which 6 cycles of intra vitreous chemotherapy with methotrexate were applied, he showed an excellent response, and recovered all his neurological functions except that right hemianopia persist. Control MRI showed partial response at 2nd cycle and complete response after the 4th cycle. No Radiation was performed. CONCLUSION This report highlights the fact that pediatric PCNSL may be effectively treated by a combination of HDMTX and rituximab-based chemoimmunotherapy without irradiation. Lack of awareness of this rare entity may lead to extense resections of brain, and potential permanent secuelae that were avoided in this illustrative case.

scholarly journals GCT-15. INTEGRATED CLINICAL, HISTOPATHOLOGICAL, AND MOLECULAR DATA ANALYSIS OF 190 CENTRAL NERVOUS SYSTEM GERM CELL TUMORS FROM THE IGCT CONSORTIUM

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii330-iii331
Author(s):  
Hirokazu Takami ◽  
Koichi Ichimura ◽  
Kohei Fukuoka ◽  
Akitake Mukasa ◽  
Nobuhito Saito ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Basal Ganglia ◽  
Pineal Gland ◽  
Germ Cell ◽  
Prognostic Significance ◽  
Germ Cell Tumors ◽  
Molecular Data ◽  
Molecular Heterogeneity ◽  
Intracranial Germ Cell Tumor

Abstract BACKGROUND We integrated clinical, histopathological, and molecular data of central nervous system germ cell tumors to provide insights into their management. METHODS Data from the Intracranial Germ Cell Tumor Genome Analysis Consortium were reviewed. A total of 190 cases were classified as primary GCTs based on central pathological reviews. RESULTS All but one of the cases that were bifocal (neurohypophysis and pineal glands) and cases with multiple lesions including neurohypophysis or pineal gland were germinomas (34 of 35). Age was significantly higher in patients with germinoma than other histologies. Comparison between tumor marker and histopathological diagnoses showed that 18.2% of histopathologically diagnosed germinomas were marker-positive and 6.1% of non-germinomatous GCTs were marker-negative, suggesting a limitation in the utility of markers or histopathology alone using small specimens for diagnosis. Comparison between local and central histopathological diagnoses revealed a discordance of 12.7%. Discordance was significantly less frequent in biopsy cases, implying difficulty in detecting all histopathological components of heterogeneous GCTs. Germinomas at the typical sites (neurohypophysis or pineal gland) showed a better PFS than those at atypical sites (p=0.03). A molecular-clinical association study revealed frequent MAPK pathway mutations in males (51.4 vs 14.3 %, p=0.007), and PI3K/mTOR pathway mutations in basal ganglia cases (p=0.004). Basal ganglia cases also had frequent chromosomal losses. Some chromosomal aberrations (2q, 8q gain, 5q, 9p/q, 13q, 15q loss) showed potential prognostic significance. CONCLUSIONS These in-depth findings of this study regarding the clinical and molecular heterogeneity will increase our understanding of the pathogenesis of this enigmatic tumor.

scholarly journals Chemotherapy-colchicine interaction in a child with Familial Mediterranean Fever and Hodgkin Lymphoma

2018 ◽  
Vol 10 (1) ◽  
pp. e2018019 ◽  
Author(s):  
Karin Petra Sabine Langenberg-Ververgaert ◽  
Ronald M. Laxer ◽  
Angela S. Punnett ◽  
Lee L Dupuis ◽  
Yaron Finkelstein ◽  
...  
Keyword(s):  
Familial Mediterranean Fever ◽  
Hodgkin Lymphoma ◽  
Pediatric Patient ◽  
Hematological Malignancies ◽  
Nodular Sclerosis ◽  
Mediterranean Fever

Familial Mediterranean Fever (FMF) has been associated with hematological malignancies, but has not been reported in association with Hodgkin lymphoma (HL). We hereby describe the first pediatric patient with FMF and stage IIA nodular sclerosis HL. She was treated with prednisone, doxorubicin, vincristine and etoposide (OEPA). However, she suffered more than expected treatment-related toxicity due to interaction with colchicine. Colchicine had to be discontinued during her second cycle of chemotherapy which was well tolerated. She is currently in remission at 17 months after her HL diagnosis, and her FMF is under control with colchicine without any signs of toxicity.

Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment

Blood ◽  
2003 ◽  
Vol 101 (2) ◽  
pp. 466-468 ◽  
Author(s):  
James L. Rubenstein ◽  
Dan Combs ◽  
Jay Rosenberg ◽  
Arthur Levy ◽  
Michael McDermott ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Hodgkin Lymphoma ◽  
Phase 1 ◽  
Central Nervous System Lymphoma ◽  
Serum Levels ◽  
Pharmacokinetic Analysis ◽  
Lymphomatous Meningitis ◽  
Cell Surface Molecule ◽  
Non Hodgkin Lymphoma

Most lymphomas that involve the central nervous system are B-cell neoplasms that express the cell surface molecule CD20. After intravenous administration, rituximab can be reproducibly measured in the cerebrospinal fluid (CSF) in patients with primary central nervous system lymphoma; however, the CSF levels of rituximab are approximately 0.1% of serum levels associated with therapeutic activity in patients with systemic non-Hodgkin lymphoma. Because lymphomatous meningitis is a frequent complication of non-Hodgkin lymphoma, we have conducted an analysis of the safety and pharmacokinetics of direct intrathecal administration of rituximab using cynomolgus monkeys. No significant acute or delayed toxicity, neurologic or otherwise, was detected. Pharmacokinetic analysis suggests that drug clearance from the CSF is biphasic, with a terminal half-life of 4.96 hours. A phase 1 study to investigate the safety and pharmacokinetics of intrathecal rituximab in patients with recurrent lymphomatous meningitis will be implemented based on these findings.

Sign in / Sign up

Export Citation Format

Share Document